Micelles from polyethylene glycol/phosphatidylethanolamine conjugates for tumor drug delivery

Journal of Controlled Release

Volumn 91, Issue 1-2, 2003, Pages 97-102

  Lukyanov, Anatoly N ^a   Gao, Zhonggao ^a   Torchilin, Vladimir P ^a  

^a NORTHEASTERN UNIVERSITY   (United States)

Author keywords

Anticancer antibody; Immunomicelles; PEG lipid conjugates; Polymeric micelles; Tumor targeting

Indexed keywords

IMPLANTS (SURGICAL); MICELLES; POLYETHYLENE GLYCOLS; TUMORS;

ANTICANCER AGENTS; LEWIS LUNG CARCINOMA (LLC);

CONTROLLED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CHLORINE DERIVATIVE; DEQUALINIUM; MACROGOL DERIVATIVE; MACROGOL PHOSPHATIDYLETHANOLAMINE CONJUGATE; PACLITAXEL; TAMOXIFEN; UNCLASSIFIED DRUG; EXCIPIENT; PHOSPHATIDYLETHANOLAMINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CANCER TRANSPLANTATION; CONFERENCE PAPER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; FEMALE; LUNG CARCINOMA; MICELLE; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ARTICLE; C57BL MOUSE; CHEMISTRY; ENZYME LINKED IMMUNOSORBENT ASSAY; NEOPLASM; PARTICLE SIZE; PATHOLOGY; SOLUBILITY;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DELIVERY SYSTEMS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXCIPIENTS; FEMALE; MICE; MICE, INBRED C57BL; MICELLES; NEOPLASMS; PARTICLE SIZE; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; SOLUBILITY;

EID: 0141921484     PISSN: 01683659     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-3659(03)00217-7     Document Type: Conference Paper

References (15)

1. Trubetskoy V.S., Torchilin V.P. Use of polyoxyethylene-lipid conjugates as long-circulating carriers for delivery of therapeutic and diagnostic agents. Adv. Drug Deliv. Rev. 16:1995;311-320.
2. Lukyanov A.N., Gao Z., Mazzola L., Torchilin V.P. Polyethylene glycol-diacyllipid micelles demonstrate increased accumulation in subcutaneous tumors in mice. Pharm. Res. 19:2002;1424-1429.
3. Gao Z., Lukyanov A.N., Singhal A., Torchilin V.P. Diacyl-polymer micelles as nanocarriers for poorly soluble anticancer drugs. Nano Lett. 2:2002;979-982.
4. Yuan F., Leunig M., Huang S.K., Berk D.A., Papahadjopoulos D., Jain R.K. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res. 54:1994;3352-3356.
5. Gabizon A.A. Liposome circulation time and tumor targeting: implications for cancer therapy. Adv. Drug Deliv. Rev. 16:1995;285-294.
6. Maeda H., Wu J., Sawa T., Matsumura Y., Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J. Control. Release. 65:2000;271-284.
7. Gabizon A.A. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 19:2001;424-436.
8. Parr M.J., Masin D., Cullis P.R., Bally M.B. Accumulation of liposomal lipid and encapsulated doxorubicin in murine Lewis lung carcinoma: the lack of beneficial effects by coating liposomes with poly(ethylene glycol). J. Pharmacol. Exp. Ther. 280:1997;1319-1327.
9. Weissig V., Whiteman K.R., Torchilin V.P. Accumulation of protein-loaded long-circulating micelles and liposomes in subcutaneous Lewis lung carcinoma in mice. Pharm. Res. 15:1998;1552-1556.
10. Iakoubov L.Z., Torchilin V.P. A novel class of antitumor antibodies: nucleosome-restricted antinuclear autoantibodies (ANA) from healthy aged nonautoimmune mice. Oncol. Res. 9:1997;439-446.
11. Iakoubov L.Z., Torchilin V.P. Nucleosome-releasing treatment makes surviving tumor cells better targets for nucleosome-specific anticancer antibodies. Cancer Detect. Prev. 22:1998;470-475.
12. Torchilin V.P., Levchenko T.S., Lukyanov A.N., Khaw B.A., Klibanov A.L., Rammohan R., Samokhin G.P., Whiteman K.R. p-Nitrophenylcarbonyl-PEG-PE- liposomes: fast and simple attachment of specific ligands, including monoclonal antibodies, to distal ends of PEG chains via p-nitrophenylcarbonyl groups. Biochim. Biophys. Acta. 1511:2001;397-411.
13. Torchilin V.P., Rammohan R., Weissig V., Levchenko T.S. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc. Natl. Acad. Sci. USA. 98:2001;8786-8791.
14. Park J.W., Kirpotin D.B., Hong K., Shalaby R., Shao Y., Nielsen U.B., Marks J.D., Papahadjopoulos D., Benz C.C. Tumor targeting using anti-her2 immunoliposomes. J. Control. Release. 74:2001;95-113.
15. Weissig V., Lizano C., Torchilin V.P. Micellar delivery system for dequalinium - a liphophilic cationic drug with anticarcinoma activity. J. Liposome Res. 8:1998;391-400.